Nesina Tablet, Film Coated
Product Images NDC 64764-250

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Nesina (NDC 64764-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Nesina 01)

Chemical structure diagram of alogliptin, the active ingredient in Nesina tablets. The structure shows the molecular arrangement including a cyclohexylamine group and nitrile substituent, along with benzoic acid as a separate component.*

FDA Label Image

Figure 1 (Nesina 02)

A forest plot chart showing the pharmacokinetic interaction of alogliptin (Nesina) with various coadministered drugs. The chart presents ratios and 90% confidence intervals (CI) for area under the curve (AUC) and maximum concentration (Cmax) comparing alogliptin combined with other drugs versus each drug alone. The chart includes drugs metabolized by various CYP450 enzymes and Pgp substrates, with all recommendations indicating no dose adjustment needed.*

FDA Label Image

Figure 2 (Nesina 03)

A chart showing the pharmacokinetic interaction of alogliptin 25 mg with various coadministered drugs, including metformin, cimetidine, gemfibrozil, pioglitazone, fluconazole, ketoconazole, atorvastatin, cyclosporine, and digoxin. The graph plots the ratio and 90% confidence interval of alogliptin with each drug compared to alogliptin alone, alongside recommendations indicating no dose adjustment is necessary for all combinations.*

FDA Label Image

Figure 3 (Nesina 04)

A bar chart comparing least squares mean change in A1C (%) among treatment groups including Placebo, Nesina (alogliptin) 25 mg, Pioglitazone 15 mg, 30 mg, and 45 mg, and combinations of Nesina plus Pioglitazone. The chart shows greater reduction in A1C for combination treatments compared to single agents or placebo, with statistical significance indicated for combination therapies.*

FDA Label Image

Figure 4 (Nesina 05)

A Kaplan-Meier cumulative event probability graph comparing Nesina (alogliptin) and placebo over 30 months from randomization. The x-axis shows months, and the y-axis shows event probability. Two curves represent Nesina (dashed line) and placebo (solid line), with numbers at risk listed below. A hazard ratio with 98% confidence interval is noted comparing Nesina to placebo.*

FDA Label Image

6-25bottlelabel (Nesina 06)

Label for Nesina (alogliptin) 6.25 mg film-coated tablets by Takeda Pharmaceuticals America, Inc. The label includes dosage strength, quantity of 30 tablets, dosing instructions to dispense with medication guide, storage instructions, and a barcode with NDC number 64764-625-30.*

FDA Label Image

12-5bottlelabel (Nesina 07)

Label of Nesina (alogliptin) tablets 12.5 mg, oral film-coated tablets distributed by Takeda Pharmaceuticals America, Inc. The label includes dosage instructions, storage information, a barcode, and indicates a package size of 30 tablets. It also advises dispensing with a medication guide.*

FDA Label Image

25bottlelabel (Nesina 08)

Nesina (alogliptin) 25 mg film-coated tablets label with a 30-tablet count. The label includes dosage instructions, storage conditions, and distributor information from Takeda Pharmaceuticals America, Inc. The packaging highlights the active ingredient strength and states to dispense with medication guide. It also features barcodes and regulatory information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.